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Abstract
 
OX40 expressed on activated T cells is known to be an important costimulatory molecule on
T cell activation in vitro. However, the in vivo functional significance of the interaction be-
tween OX40 and its ligand, OX40L, is still unclear. To investigate the role of OX40L during
in vivo immune responses, we generated OX40L-deficient mice and a blocking anti-OX40L
monoclonal antibody, MGP34. OX40L expression was demonstrated on splenic B cells after
CD40 and anti-immunoglobulin (Ig)M stimulation, while only CD40 ligation was capable of
inducing OX40L on dendritic cells. OX40L-deficient and MGP34-treated mice engendered
apparent suppression of the recall reaction of T cells primed with both protein antigens and al-
loantigens and a significant reduction in keyhole limpet hemocyanin–specific IgG production.
The impaired T cell priming was also accompanied by a concomitant reduction of both T helper
type 1 (Th1) and Th2 cytokines. Furthermore, antigen-presenting cells (APCs) derived from the
mutant mice revealed an impaired intrinsic APC function, demonstrating the importance of
OX40L in both the priming and effector phases of T cell activation. Collectively, these results
provide convincing evidence that OX40L, expressed on APCs, plays a critical role in antigen-
specific T cell responses in vivo.
Key words: OX40 ligand • antigen-presenting cell function • T cell priming • OX40 ligand 
mutant mice • cytokine
 
Introduction
 
OX40, a membrane glycoprotein of the TNF receptor
family originally identified as an activated T cell marker in
the rat (1–3), has also been demonstrated on activated T
cells in humans and mice (4–6). Recently, further investi-
gations have revealed the presence of OX40-expressing T
cells at inflammatory sites of various diseases (7–14). OX40
ligand (OX40L), a type II membrane protein, was identi-
fied as the mouse homologue of human gp34, which we
molecularly cloned as a target molecule for a transacting
transcriptional activator, Tax, of the human T cell lympho-
tropic virus type I (15). Expression of OX40L, initially de-
scribed on human T cell lymphotropic virus type I–infected
T cells (15), has been found on murine B cells (16, 17), hu-
man endothelial cell lines (18), dendritic cells (19, 20), and
recently among a population of APCs in the central ner-
vous system during the course of clinically apparent experi-
mental allergic encephalomyelitis (EAE)
 
1
 
 (14).
Initiation of antigen-specific T cell responses requires an
antigen presented by MHC molecules and costimulatory
signals provided by APCs (21, 22). Furthermore, OX40–
OX40L has recently been reported to be implicated in the
additional costimulatory signals in vitro (4, 5, 23–25). In-
tervention of the OX40–OX40L system has produced in-
teresting findings in immune modulation. Cross-linking of
 
1
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OX40 with an anti-OX40 Ab generated a costimulatory
signal in CD4
 
1
 
 T cells (1, 4, 5, 23). An anti-OX40 polyclonal
Ab that blocked the interaction between OX40 and OX40L,
and a soluble (s)OX40-Ig fusion protein that led to an en-
hanced proliferation and Ig production of B cells have been
able to highlight the significance of OX40L in the terminal
differentiation of activated B cells (16, 17). Similarly, liga-
tion of OX40L expressed on human dendritic cells report-
edly enhanced dendritic cell differentiation in vitro (19),
thus correlating with an antigen-presenting function as a
consequence of OX40L ligation.
Weinberg et al. previously reported the expression of
OX40 on autoreactive T cells in rats with EAE, and that ad-
ministration of an OX40 immunotoxin resulted in an ame-
lioration of this disease (7). Moreover, an sOX40 fusion pro-
tein, antagonist for OX40L, has also been described not only
to suppress ongoing EAE (14) and semiallogeneic graft-versus-
host disease (12), but also to ameliorate ongoing colitis in
murine models of inflammatory bowel disease (13). These
observations shed further light on the requirement of the
costimulatory function offered by the OX40–OX40L sys-
tem in the regulation of immune disorders.
Our report shows that OX40 and OX40L are an indis-
pensable pair in in vivo T cell priming as demonstrated by
lack of functional OX40L expression on APCs, through
the use of OX40L-deficient mice and an mAb antagonistic
to OX40L.
 
Materials and Methods
 
Generation of OX40L-deficient Mice.
 
A phage clone containing
an 
 
z
 
13-kb DNA fragment, including exon 1 of the OX40L gene,
was isolated from a mouse 129/Sv genomic library (Stratagene)
by using the OX40L cDNA as a probe. The vector was constructed
by replacement of the first exon with a neomycin resistance cas-
sette (PGKNeo [26]; see Fig. 1 A). The gene for the diphtheria
toxin A subunit (DT-A) was incorporated into the 3
 
9
 
 end of the
vector. The vector was linearized with NotI and electroporated
into J1 embryonic stem (ES) cells. G418-resistant ES cell colonies
were picked up, expanded as described previously (27), and screened
for homologous recombination by Southern blotting using a
flanking probe depicted in Fig. 1 A. Three ES clones were iden-
tified as heterozygous for OX40L disruption and injected into
blastocysts derived from C57BL/6 Cr mice. Chimeric mice were
bred against C57BL/6 Cr female mice, and the generated F1 mice
heterozygous for the mutation were intercrossed to generate F2
offspring. The offspring were analyzed for the mutated OX40L
allele by Southern blotting. The OX40L-deficient mice were
backcrossed at least six times to C57BL/6 Cr mice for in vivo
immunological analyses.
 
Preparation of MGP34, an mAb Specific for Mouse OX40L.
 
BW5147, a mouse T cell hybridoma cell line, was stably trans-
fected with pSRmgp34 expression plasmid carrying the SR
 
a
 
 pro-
moter followed by mouse OX40L cDNA, yielding BW-gp34.
TART-1, a rat T cell line, was stably transfected with pBCMG-
Sneo-mgp34 expression plasmid carrying the CMV promoter fol-
lowed by mouse OX40L cDNA, yielding TART-gp34. Cells used
were cultured in RPMI 1640 medium containing 10% FCS.
Wistar rats were intraperitoneally immunized four times at weekly
intervals with 10
 
8
 
 TART-gp34 cells. The sensitized spleen cells
were fused with a mouse myeloma cell line, SP2/0-Ag14, and hy-
bridoma clones were obtained as described previously (28). Culture
supernatants of the hybridomas were screened by a radioimmu-
noassay with 
 
125
 
I-labeled anti–rat sheep Ig (IM1320; Amersham
Pharmacia Biotech) using the transfectant cell lines. One hybrid-
oma producing mAb specific for mouse OX40L was positively
screened and named MGP34.
 
Surface Labeling and Immunoprecipitation.
 
Cell surface proteins
of BW5147 and BW-gp34 cells were biotinylated using biotin–
CNHS-ester (Boehringer Mannheim). The cells (10
 
7
 
) were solu-
bilized in 1 ml of buffer (25 mM Tris-HCl, pH 7.5, 140 mM NaCl,
1 mM EDTA, 2 mM PMSF, 0.1% aprotinin, and 1% NP-40).
Protein A–Sepharose was pretreated with anti–rat IgG and then
conjugated with the MGP34 mAb. The cell lysates were incu-
bated with the protein A–Sepharose for 2 h at 4
 
8
 
C. Immunopre-
cipitates bound to the Sepharose were separated by SDS-PAGE
with a 12.5% polyacrylamide gel and transferred to polyvinylidene
difluoride filters (Millipore). The filters were probed with strepta-
vidin–horseradish peroxidase and visualized by the ECL detec-
tion system (Amersham Pharmacia Biotech).
 
mAbs.
 
MGP34 (rat IgG2c) specific for mouse OX40L estab-
lished here was conjugated to NHS-LC-biotin (Pierce Chemical
Co.). Anti-CD4 (L3T4), B220 (RA3-6B2), anti-CD11c (HL3),
anti-CD40 (HM40-3), and anti–mouse IgM (R6-60.2) dye-
linked mAbs for immunofluorescence studies were all purchased
from PharMingen. Anti–human Fc-FITC was purchased from
Cappel. The specificity and optimal titer of the mAbs were deter-
mined before use.
 
Immunofluorescence Staining.
 
Preincubation with normal rat se-
rum was carried out to prevent nonspecific association of labeled
mAbs, including binding to the Fc receptor. The cells were incu-
bated for 30 min at 4
 
8
 
C with biotin-conjugated MGP34 in combi-
nation with anti-IgM–FITC plus B220-PE for B cells or anti-
CD11c–FITC plus 33D1-PE for dendritic cells. The cells labeled
with the biotinylated mAb were visualized by streptavidin-allophy-
cocyanin (PharMingen), and subjected to flow cytometric analysis.
For negative control of OX40L, preincubation of the cells with
unlabeled MGP34 was performed to abolish any specific staining
by the biotinylated Abs. The mAb-treated cells were analyzed with
a FACSCalibur™ flow cytometer (Becton Dickinson).
 
Preparation and Activation of Dendritic Cells.
 
The enriched den-
dritic cells were prepared as described (29). In brief, collagenase-
treated spleen cells (Collagenase type IV; Sigma Chemical Co.) in
RPMI 1640 were suspended in 1.077 g/ml Nycodenz (Nyco-
prep A; Nycomed) and centrifuged at 600 
 
g
 
 for 20 min, and the
low density fraction was collected and washed several times. The
recovered cells were suspended and incubated in RPMI 1640 con-
taining 10% FCS for 2 h at 37
 
8
 
C to remove nonadherent cells, and
the remaining adherent cells were incubated overnight at 37
 
8
 
C in
the medium plus mouse recombinant GM-CSF (5 ng/ml) and IL-4
(2 ng/ml) (PeproTech). After cultivation, the nonadherent cells
harvested contained 
 
.
 
60% CD11c
 
1
 
33D1
 
1
 
 dendritic cells. The
enriched cells were cultured in the presence of anti-CD40 mAb
(HM40-3, 5 
 
m
 
g/ml) plus goat anti–hamster Ab (5 
 
m
 
g/ml; Caltag)
in RPMI 1640 including 10% FCS at 37
 
8
 
C for the indicated times.
 
In Vivo T Cell Priming and Recall Response Stimulated with Pro-
tein Antigens.
 
6-wk-old female C57BL/6 mice, OX40L-defi-
cient mice, or wild-type littermates (
 
n
 
 5 
 
4 per each group) were
immunized with 50 
 
m
 
g of KLH, hen egg lysozyme (HEL), or
OVA, together with CFA in a total volume of 50 
 
m
 
l into each
hind footpad. The C57BL/6 mice were injected intraperitoneally
with 500 
 
m
 
g of MGP34 or rat IgG (Cappel) at days 0, 3, and 6 of
immunization. On day 9 after immunization, inguinal lymph node 
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cells on the antigen-immunized side were extracted. The lymph
node cells (10
 
5
 
) were added into each well of a 96-well plate and in-
cubated with the indicated dose of the proteins at 37
 
8
 
C for 3 d. Al-
ternatively, CD4
 
1
 
 T cells (5 
 
3 
 
10
 
4
 
) purified from the lymph node
were restimulated with KLH in the presence of APCs (2.5 
 
3 
 
10
 
5
 
) in
the same manner. The CD4
 
1
 
 T cells used were purified from the
extracted lymph node by using mouse anti-CD4 Dynabeads
 
®
 
 (Dy-
nal) and further separated from the beads using DETACHaBEAD
 
®
 
(Dynal). Purity was confirmed to be 
 
.
 
98% by flow cytometer. The
APCs used were isolated from the spleens of 6-wk-old female
C57BL/6 mice, OX40L-deficient mice, or wild-type littermates and
irradiated (3,000 rad). The cells cultured were assayed for [
 
3
 
H]thymi-
dine uptake and cytokine production in response to KLH in vitro as
described previously (28, 30, 31). Culture supernatants were col-
lected at 48 h for IL-2, or at 96 h for IL-5, IL-10, and IFN-
 
g
 
, and
were subjected to ELISA to measure the cytokine production.
 
In Vivo Production of KLH-specific Ab.
 
80 
 
m
 
g of KLH was used
to immunize the OX40L-deficient and wild-type mice as de-
scribed above, except that the mice were immunized again with
50 
 
m
 
g of KLH by the same method 4 wk after priming to elicit
the secondary Ab response. For the primary Ab determination,
serum was collected on day 7 for IgM and day 14 for the IgGs to
examine the concentration of anti–KLH-specific Abs. For sec-
ondary Ab production, serum was collected on day 5 after the
second immunization.
 
Assay for Anti–KLH-specific Ig Production.
 
Each well of an ELISA
microtiter plate was coated with 10 
 
m
 
g/ml of KLH in carbonate
buffer, pH 9.0, by overnight incubation at 4
 
8
 
C. Plates were washed
and subsequently blocked with 1% BSA in PBS for 1 h at 37
 
8
 
C.
Murine sera from OX40L-deficient or wild-type mice, diluted in
PBS containing 1% BSA (from 1:100 to 1:100,000), were added
to the wells and incubated for 2 h at room temperature. The
plates were then washed, and bound Abs were detected by incu-
bation with goat anti–murine IgM, IgG1, IgG2a, IgG2b, or IgG3
conjugated to alkaline phosphatase (1:200; Southern Biotechnol-
ogy Associates). After an additional 1-h incubation, color reac-
tions were performed using alkaline phosphatase substrate (Sigma
Chemical Co.) in a diethanolamine buffer. The reaction was
stopped by 3 M NaOH, and the OD readings at 405 nm from the
dilution (1:300, 1:900, 1:2,700, or 1:8,100 for IgM and IgG3,
IgG2a, IgG2b, or IgG1, respectively) were evaluated. This was
demonstrated to be well within the linear part of the titration curve.
 
CTL Induction and Cytotoxicity Assay.
 
To induce a CTL re-
sponse, OX40L-deficient, wild-type, MGP34-treated, or control
IgG–treated C57BL/6 mice (
 
n
 
 5 
 
4 per group), as recipients,
were immunized intraperitoneally with 5 
 
3 
 
10
 
7
 
 irradiated sple-
nocytes from BALB/c mice. In the Ab-treated groups, the mice
were then administered intraperitoneally with 500 
 
m
 
g MGP34 or
a control Ab on days 0, 2, and 4. On day 5, spleen cells were ex-
tracted and prepared as effector cells in 
 
51
 
Cr-release assays. BALB/c
splenocytes stimulated with ConA (10 
 
m
 
g/ml) were used as target
cells as described previously (32). After incubating the 
 
51
 
Cr-labeled
target cells with the effector cells, radioactivities of the supernatants
were determined with a 
 
g
 
-counter. Results were expressed as fol-
lows: % specific lysis 
 
5 
 
[(release in test – spontaneous release)/
(maximum release – spontaneous release)] 
 
3
 
 100.
 
Results
 
Generation and Characterization of OX40L-deficient Mice.
 
Using gene targeting and ES cell technology, the OX40L
mutation was created by inserting the neomycin resistance
gene cassette into the first exon, and was introduced into
ES cells through homologous recombination as illustrated in
Fig. 1 A. Homologous recombination events were geno-
typed by Southern blot analysis. Three ES clones carrying
the mutant allele were isolated to generate chimeric mice.
Chimeric mice derived from two of the three ES clones
were found to transmit the mutant allele to their offspring.
Wild-type, homozygous mutant, and heterozygous mutant
genotypes were determined by Southern blot analyses of
DNA from the progeny obtained by interbreeding of het-
erozygous mice (Fig. 1 B). 10.0- and 3.0-kb bands were
detected as mutated and wild-type alleles, respectively (Fig.
1 B), by a flanking probe depicted in Fig. 1 A. To examine
the expression of OX40L, flow cytometric analysis with
splenic B cells from wild-type and homozygous mice was
carried out. Since expression of OX40L on all freshly iso-
lated lymphocyte populations in wild-type mice was unde-
tectable, B cells from both wild-type and mutant mice
were selected and stimulated with anti-CD40 plus anti-
IgM Ab for 3 d to induce OX40L expression. Activated
B cells from the wild-type mice had strong expression of
OX40L, whereas no expression was observed on the B
Figure 1. Creation of OX40L-deficient mice. (A) Structure of the
wild-type and mutant OX40L alleles. The targeting construct was de-
signed to replace the first exon (black box) with a PGKneo gene cassette.
The location of the probe for hybridization, the 0.8-kb PvuII-StuI frag-
ment, is shown (hatched box). (B) Southern blot analysis of offspring of
the germline chimera. Tail DNA harvested from wild-type, OX40L1/2,
and OX40L2/2 mice was digested with HindIII (the location of which is
depicted as H in A), electrophoresed, and probed with the radiolabeled
probe. The mutant and wild-type alleles gave 10.0- and 3.0-kb hybridiz-
ing bands, respectively. (C) FACS® analysis of surface expression of
OX40L. Splenic B cells from wild-type and OX40L2/2 mice were stim-
ulated with anti-CD40 plus anti-IgM, and then stained with anti–mouse
OX40L mAb, MGP34. 
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cells from the homozygous mice (Fig. 1 C), indicating that
the mutation of the OX40L allele resulted in lack of
OX40L expression on the cell surfaces. OX40L knockout
mice had been backcrossed onto the C57BL/6 Cr back-
ground up to at least six generations before all immunolog-
ical analyses.
 
Establishment of MGP34, Antagonistic mAb Specific for
OX40L.
 
MGP34 was prepared by immunization with
TART-1 transfectant cells expressing mouse OX40L. Speci-
ficity of MGP34 was determined by staining of BW-gp34
cells, stably transfected with mouse OX40L, and their pa-
rental BW5147 cells. MGP34 reacted to BW-gp34, but not
to BW5147 cells (Fig. 2 A), demonstrating the specificity of
the mAb for OX40L. MGP34 detected a 34-kD band in
the immunoprecipitates from biotinylated BW-gp34 cells
(Fig. 2 B), indicating that the mouse OX40L protein ex-
pressed on the cell surface is a 34-kD molecule similar to
human OX40L in molecular mass (33).
To examine the effect of MGP34 on the OX40–OX40L
interaction, competitive binding assays were performed be-
tween a human sOX40-Fc fusion protein (provided by Dr.
P. Baum, Immunex Research and Development Corp., Se-
attle, WA) and MGP34 to BW-gp34 cells. sOX40–Fc ap-
parently bound to BW-gp34 cells in the presence of the con-
trol mAb, whereas the binding was completely eliminated in
the presence of MGP34 (Fig. 2 C), clearly indicating an ef-
fective blocking potential of MGP34 towards the binding
between OX40 and OX40L.
The OX40L–OX40 system is known to be implicated in
costimulatory signal transduction in activated T cells (1, 4, 5,
23–25). To assess the inhibitory effect of MGP34 on OX40-
dependent T cell proliferation, T cells purified from spleens
were stimulated with anti-CD3 plus irradiated BW-gp34 cells
or anti-CD3 plus irradiated BW5147 parental cells, in the
presence of either MGP34 or a control mAb, and then assayed
for their [
 
3
 
H]thymidine uptake. Stimulation of T cells with
BW-gp34 cells induced a significant increase in [
 
3
 
H]thymi-
dine uptake compared with the BW5147 parental cells in the
presence of the control IgG. However, the enhancement in T
cell proliferation by OX40L was completely suppressed by
MGP34 (Fig. 2 D), and in a dose-dependent manner (Fig.
2 E). These results indicate that MGP34 has an inhibitory ef-
fect towards T cell proliferation in response to OX40L in vitro.
 
Expression Kinetics of OX40L on T, B, and Dendritic Cells.
 
Although accumulating evidence currently demonstrates the
expression of OX40L on T, B, and dendritic cells in hu-
mans and mice (15, 16, 19, 20, 25), the expression kinetics
of OX40L is still unclear. Therefore, we carried out a de-
tailed analysis of OX40L expression by immunostaining
with MGP34. Thymocytes and splenic lymphocytes freshly
isolated from 5-wk-old C57BL/6 male mice failed to ex-
press OX40L (data not shown). Splenic T and B cells were
stimulated with anti-CD3 and anti-CD40 plus anti-IgM
Ab, respectively. Little expression of OX40L was observed
on both CD4
 
1
 
 and CD8
 
1
 
 T cells stimulated with anti-
CD3 (data not shown). However, in the B220
 
1 
 
IgM
 
1
 
 B
cell population, stimulation with anti-CD40 plus anti-IgM
Ab was able to induce expression of OX40L 2 d after the
Figure 2. Binding specificity and blocking potential of MGP34. (A)
Specificity of MGP34 for OX40L. BW5147 parental cells (left) and
BW5147 cells transfected with mouse OX40L, BW-gp34 (right), were
stained with MGP34 and analyzed by flow cytometry. Dotted lines repre-
sent control stainings conducted in the presence of excess unlabeled
MGP34; solid lines represent MGP34-specific staining. (B) Immunopre-
cipitation of mouse OX40L with MGP34. BW5147 and BW-gp34 cells
were surface-labeled with biotin, lysed, and immunoprecipitated with
MGP34. Arrowhead, a 34-kD precipitate. Numbers on the left indicate
standard molecular sizes. (C) Competitive binding of sOX40-Fc and
MGP34 to OX40L. BW-gp34 cells were preincubated with MGP34 or
control IgG, and incubated with sOX40-Fc at 48C for 30 min. The bind-
ing of the sOX40-Fc (provided by Dr. P. Baum) was visualized by anti–
human Fc-FITC. Solid thick or dotted line represents sOX40-Fc binding
in the presence of MGP34 or the control Ab, respectively. Solid thin line
represents background staining with anti–human Fc-FITC alone. (D)
Blocking effect of MGP34 on the OX40-dependent proliferation of T
cells. Purified splenic T cells (105/well) were assayed for their prolifera-
tion induced by immobilized anti-CD3 in the presence of irradiated
BW5147 (black bars) or BW-gp34 cells (5 3 104; white bars). The cells
were cultured for 72 h in the presence of 10 mg/ml of MGP34 or the
control Ab, and assayed for thymidine incorporation. (E) The inhibitory
effect of MGP34 is dose dependent. Purified splenic T cells (105/well)
were cocultured with irradiated BW-gp34 cells (5 3 104/well) in the
presence of anti-CD3 at the indicated concentrations of MGP34 (black
bars) or control IgG (white bars). The proliferative response was assessed
at 72 h as described above. 
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stimulation (Fig. 3), and the expression persisted for up to
7 d. Stimulation with either anti-CD40 or anti-IgM Ab did
not induce any expression of OX40L (data not shown).
CD11c
 
1
 
33D1
 
1
 
 dendritic cells freshly isolated from spleen
cells expressed little, if any, OX40L; however, the OX40L
expression was significantly induced 1 d after stimulation
with anti-CD40 (Fig. 3), but not by LPS (data not shown),
and was sustained up until at least day 7. These results sug-
gest that CD40 signaling is indispensable for OX40L ex-
pression on both B and dendritic cells.
 
Phenotypes of Lymphocytes and Dendritic Cells in OX40L-
deficient Mice.
 
Flow cytometric analyses of thymocytes and
splenocytes were performed to examine whether an absence
of OX40L expression affects the development of lympho-
cytes and dendritic cells. OX40L-deficient mice did not
display any apparent abnormality in the formation of lym-
phoid organ structures, in the numbers of T and B cells, and
in the phenotypes of these cells as assessed by CD4 and CD8,
or B220 and IgM expression on thymocytes and splenic
lymphocytes (data not shown), respectively. No obvious dif-
ference in the ratio of CD11c
 
1
 
33D1
 
1
 
 dendritic cells was ob-
served between OX40L-deficient and wild-type spleens (data
not shown). These results suggest that OX40L is not crucial
in the early development of T, B, and dendritic cells.
To gain further insight into the role played by OX40L in
APC functions, we examined the B and dendritic cells of
OX40L-deficient mice in their expression of several mole-
cules known to be involved in APC functions such as MHC
class II antigen, CD40, CD80, and CD86. Although a previ-
ous report demonstrated that cross-linking of OX40L in-
creased the expression level of these costimulatory molecules
on human dendritic cells (19), similar basal levels of expres-
sion of these molecules were observed on unstimulated B
and dendritic cells in both OX40L-deficient and wild-type
mice (data not shown). Since CD40-stimulated B and den-
dritic cells are considered to be functional APCs, we next
examined the expression patterns of these activated APC
markers on B and dendritic cells upon stimulation with
anti-CD40. All of these molecules were expressed among
both CD40-stimulated B and dendritic cells derived from
wild-type and OX40L-deficient mice (data not shown), sug-
gesting that the absence of OX40L does not affect the
CD40-induced expression of such molecules on APCs.
Proliferative responses of splenic T and B cells obtained
from unimmunized wild-type or OX40L-deficient mice were
next evaluated. Equal levels of proliferation were observed in
both wild-type and mutant T cells in response to various T
cell stimuli (anti-CD3, anti-CD28 plus anti-CD3, ConA, or
PMA plus ionomycin). Similarly, in response to B cell stim-
uli such as LPS, anti-IgM, anti-CD40, or a combination of
anti-IgM plus anti-CD40, B cell proliferative responses were
indistinguishable in both populations (data not shown). These
results suggest that the intrinsic potential of T and B cells to
respond to antigens is preserved in OX40L-deficient mice.
 
Impairment of T Cell Priming and Cytokine Production in
OX40L-deficient Mice and MGP34-treated Mice.
 
To examine
the in vivo effect of OX40L on antigen-specific T cell acti-
vation, we immunized OX40L-deficient or wild-type mice
with KLH and tested their in vitro T cell recall proliferative
response. A significantly reduced response was observed in
OX40L-deficient mice, and the antigen dose–response
curve was shifted by several orders of magnitude (Fig. 4 A).
Similarly reduced responses were seen with two other pro-
tein antigens, hen egg lysozyme (HEL) and OVA, in OX40L-
deficient mice (Fig. 4 A). These results suggest that OX40L
plays an important role in antigen-specific T cell priming.
The reduced response in OX40L-deficient mice may be due
to a defect at the level of the APCs, since the intrinsic po-
tential of OX40L-deficient T cells in response to antigens is
preserved (data not shown) and since OX40L expression
was restricted to activated APCs but not T cells.
Next, we asked whether the dysfunction of OX40L-
deficient APCs causing the reduced reaction in the T cells oc-
curs during the initial in vivo T cell priming phase, during
Figure 3. Kinetics of OX40L expression on APCs. Splenic B cells were
cultured in the presence of anti-CD40 plus anti-IgM for the indicated time
periods. The cells were stained with anti-IgM–FITC, B220-PE, and biotiny-
lated MGP34 followed by allophycocyanin-labeled streptavidin. B2201 B
cells during the culture were examined for expression of OX40L. Enriched
splenic dendritic cells were cultured in the presence of anti-CD40 plus
anti–hamster Ab for the indicated time. The cells were stained with anti-
CD11c–FITC, 33D1-PE, and biotinylated MGP34 followed by allophyco-
cyanin-labeled streptavidin. CD11c133D11 dendritic cells during the cul-
ture were examined for expression of OX40L. Dotted lines represent control
stainings conducted in the presence of excess unlabeled MGP34; solid lines
represent MGP34-specific staining. 
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the secondary in vitro reaction, or possibly during both.
Recall proliferative assays were performed using several
configurations consisting of purified T cells and APCs de-
rived from both OX40L-deficient and wild-type mice. Ini-
tially, KLH-primed CD4
 
1
 
 T cells purified from OX40L-
deficient or wild-type mice were examined for their recall
reaction in the presence of the wild-type APCs. The re-
sponse of OX40L-deficient CD4
 
1
 
 T cells was less than half
of that observed among wild-type CD4
 
1
 
 T cells (Fig. 4 B),
indicating a key role for OX40L in antigen-specific T cell
priming in vivo. Next, to evaluate the in vitro APC func-
tion during secondary T cell activation, KLH-primed CD4
 
1
 
T cells from wild-type mice were incubated with APCs iso-
lated from OX40L-deficient or wild-type spleen, and their
recall proliferation was assayed. Interestingly, CD41 T cell
proliferation upon stimulation with the OX40L-deficient
APCs was significantly reduced compared with wild-type
APCs (Fig. 4 C). These results revealed the intrinsic dys-
function of OX40L-deficient APCs in vitro. Taking the data
together, OX40L is shown to be essential to fully activate
antigen-specific T cell responses through OX40L-express-
ing APCs during both the priming and effector phases of T
cell activation.
To rule out the possibility that the impairment of APC
function could be caused by a mismatch of MHCs between
T cells and APCs as a result of an insufficient backcross, we
also examined whether C57BL/6 mice treated with MGP34,
a blocking mAb for OX40L function, affects the in vivo T
cell priming. C57BL/6 mice were immunized with KLH
in a similar manner to the above experiment using OX40L-
deficient mice and inoculated with either MGP34 or a
control rat IgG at days 0, 2, 4, and 6 after immunization. In
vitro proliferative recall responses of their lymph node cells
were subsequently determined. Lymph node cells derived
from the MGP34-administered mice showed suppressed
recall reaction to KLH (Fig. 4 D) similar to that observed
with the OX40L-deficient mice. Furthermore, we exam-
ined the in vitro recall reaction of the CD41 T cells puri-
fied from the KLH-primed lymph nodes of MGP34-treated
mice in the presence of C57BL/6 APCs. We observed that
the MGP34-treated mice had a significant reduction in
CD41 T cell recall reaction compared with the control mice
(Fig. 4 D), confirming the critical involvement of OX40L
in antigen-specific T cell priming in vivo.
Cytokine Production in the Culture Supernatants Was Also
Assayed by ELISA. IFN-g production by both the OX40L-
deficient and MGP34-treated lymph nodes was dramati-
cally reduced (Fig. 4 E). The production levels of IL-2, IL-4,
IL-5, and IL-10 were also significantly lower than those
of the control groups (Fig. 4, E and F), suggesting that the
OX40–OX40L system critically contributes to both the Th1
and Th2 responses.
Impairment of Antigen-specific Ab Production in OX40L-defi-
cient Mice. We next investigated the role of OX40L during
the course of primary and secondary humoral immune re-
sponses against KLH, a well-known T cell–dependent anti-
gen. Sera from OX40L-deficient mice clearly exhibited re-
duced KLH-specific IgG Ab production in both primary
Figure 4. Impaired T cell priming and cytokine production in
OX40L-deficient mice and MGP34-treated mice. (A) OX40L-deficient
mice have impaired recall proliferative responses to  protein antigens.
OX40L-deficient (u) or wild-type (j) mice (four per group) were im-
munized with KLH, HEL, or OVA in the hind footpads. 9 d after immu-
nization, draining lymph nodes were extracted and subjected to an in
vitro challenge of the various protein antigens. After culturing for 3 d,
their [3H]thymidine uptake was measured. (B) Impairment of recall pro-
liferative response of the CD41 T cells of OX40L-deficient mice. Puri-
fied CD41 T cells from the draining lymph nodes of the OX40L-defi-
cient (u) or wild-type mice (j) were assayed for their recall proliferation
in response to KLH in the presence of APCs from wild-type mice. (C)
Defective APC function in OX40L-deficient mice.  Purified CD41 T
cells from the draining lymph nodes from wild-type mice primed with
KLH were assayed for their recall proliferation in response to KLH in the
presence of OX40L-deficient (u) or wild-type (j) irradiated spleen cells
used as APCs. (D) MGP34-treated mice have similarly impaired lymph
node recall proliferation to KLH. C57BL/6 mice (four per group) were
immunized in the hind footpads with KLH in CFA. On days 0, 3, and
the 6, mice received 500 mg anti-OX40L (s) or rat IgG (d) intraperito-
neally. The recall proliferative responses of the draining lymph nodes
(left) were tested in the same manner as described above. Purified CD41
T cells from the draining lymph nodes of the MGP34-treated (s) or con-
trol IgG–treated (d) mice were assayed for their recall proliferation in re-
sponse to KLH in the presence of APCs from C57BL/6 mice (right). (E
and F) Absence of OX40L or MGP34 treatment inhibits recall cytokine
production by lymph nodes in response to KLH. Production of Th1 (E)
and Th2 (F) cytokines by the draining lymph nodes of the mice in the
four groups (u, j, s, d) immunized with KLH and further subjected to
an in vitro challenge with KLH were measured.371 Murata et al.
and secondary humoral responses, among all murine IgG
subclasses (Fig. 5). No significant difference in both primary
and secondary IgM production was observed between
wild-type and OX40L-deficient mice (Fig. 5). Similarly, in
vivo administration of MGP34 mAb also inhibited the pri-
mary IgG, and not IgM, response to KLH (data not shown).
In contrast, OX40L-deficient mice demonstrated normal
IgM and IgG production specific for trinitrophenol (TNP)
in both primary and secondary responses to TNP-LPS, a T
cell–independent antigen (data not shown), indicating the
importance of the OX40–OX40L interaction in T cell–
dependent humoral responses.
Alloantigen-specific CTL Response in OX40L-deficient and
MGP34-treated Mice. We examined the effect of OX40L
on the induction of alloantigen-specific CTLs. Wild-type,
OX40L-deficient, MGP34-treated, and control IgG–treated
C57BL/6 mice used as recipients were immunized with
splenocytes derived from BALB/c mice. On day 5 after im-
munization, splenocytes from the recipient mice were used
as effector cells in the cytotoxicity assay. Allospecific CTLs
were induced in the control mice, whereas induction of
such CTLs was significantly inhibited in both OX40L-defi-
cient and MGP34-treated mice, suggesting an important
involvement of OX40L in alloantigen-specific CTL response
(Fig. 6, A and B).
Discussion
Recently, OX40 has been highlighted as a new costimu-
latory molecule capable of activating T cells; however, the
expression and function of its ligand OX40L are still un-
clear, particularly during in vivo immune responses. To elu-
cidate the in vivo significance of OX40L, we produced
OX40L-deficient mice and an antagonistic mAb specific
for OX40L, MGP34. Using the two experimental tools,
we revealed that OX40L expressed on APCs plays a key
role on antigen-specific T cell initiation in vivo.
Several in vitro studies have demonstrated that OX40
stimulation enhances IL-4 expression and promotes T cell
differentiation towards Th2 cells (34, 35). In contrast to these
Figure 5. Impaired Ab production to KLH in
OX40L-deficient mice. (A) Primary Ab responses
to KLH in wild-type (black bars) and OX40L-defi-
cient (white bars) mice were evaluated. After KLH
immunization, serum was collected on day 7 for
IgM and day 14 for the IgGs to examine the con-
centration of anti–KLH-specific Abs. (B) Second-
ary Ab responses to KLH in wild-type (black bars)
and OX40L-deficient (white bars) mice were eval-
uated. Serum was collected on day 5 after the sec-
ond immunization.
Figure 6. Suppression of CTL induction in
OX40L-deficient and MGP34-treated mice. (A)
OX40L-deficient (u) or wild-type (j) mice (H-2b)
were immunized intraperitoneally with splenocytes of
BALB/c (H-2d) mice. On day 5, CTL activities of
their splenocytes were tested with BALB/c target cells.
Data shown are representative of four experiments. (B)
C57BL/6 (H-2b) mice were immunized intraperito-
neally with splenocytes of BALB/c (H-2d) mice. The
mice were treated with 500 mg MGP34 (s) or rat IgG
(d) on days 0, 2, and 4 after immunization. On day 5,
CTL activities of their splenocytes were tested with
BALB/c target cells. Data shown are representative of
four experiments.372 Impairment of APC Function in OX40L-deficient Mice
studies, it has also been reported that in vivo administration
of an OX40-IgG fusion protein, antagonistic for OX40,
ameliorates Th1-associated diseases inflammatory bowel dis-
ease and EAE, and reduces transcripts for Th1 cytokines such
as TNF-a, IL-1, IL-12, and IFN-g in the affected tissues
(13, 14). These results suggest that OX40–OX40L interac-
tions participate in enhancing both Th1 and Th2 responses
during antigen-specific CD41 T cell activation. This study
clearly demonstrated that the lack of OX40–OX40L inter-
action inhibits both of these responses during in vivo T cell
priming. Since suppression of the Th1 response usually
induces an increase in Th2 responses and vise versa, reduc-
tion of both Th1 and Th2 cytokine production in OX40L-
deficient mice may reflect either hyporesponsiveness or
anergy in the T cell response. A consequence of OX40 liga-
tion on activated T cells is to increase their survival, as
demonstrated by a recent publication (36). To examine
whether OX40L is involved in the survival of primed mem-
ory T cells, wild-type and OX40L-deficient mice were stim-
ulated with staphylococcal enterotoxin A and LPS to induce
survival and expansion of Vb31 T cells (36, 37). Interest-
ingly, the survival of these T cells is not significantly reduced
in OX40L-deficient mice compared with wild-type mice
(Murata, K., N. Ishii, L.C. Ndhlovu, and K. Sugamura,
unpublished data). The increased survival of Vb31 T cells
by constitutive ligation of OX40 (36) might not necessarily
mean that OX40L deficiency induces apoptosis of the T
cells. To fully explain the possible mechanism of hypore-
sponsiveness of the T cells in OX40-deficient mice, further
examination will be necessary.
Further analysis of OX40L-deficient mice demonstrated
impairment of both primary and secondary Ab production
to KLH, a T cell–dependent antigen (Fig. 5, A and B), as
well as suppression of the alloantigen-specific CTL induc-
tion (Fig. 6 A) compared with wild-type mice. The sup-
pressed Ab production to KLH is similar to a previous re-
port showing that blockade of OX40–OX40L interaction
inhibited production of all of the IgG subclasses, but not
IgM (17). Since KLH is known to be a T cell–dependent
antigen on Ab production, the impairment of Ab responses
observed may also be due to suppressed T cell priming.
However, our data here cannot exclude the possibility that
OX40L signaling in B cells may be involved in Ab produc-
tion or B cell differentiation. Indeed, a previous report
demonstrated that ligation of OX40L led to an enhanced
proliferation and Ig production of B cells (16). Further-
more, the suppressed alloantigen-specific CTL induction
among OX40L-deficient mice may be a consequence of
impaired CD41 T cell help for CD8 responses. However, a
direct role of OX40–OX40L interaction on CD81 T cells
could exist, since OX40 has been reported to be expressed
on activated CD81 T cells in mice (3, 5) but not in rats.
OX40 expressed on activated T cells has been reported
to be an effector molecule for costimulatory signal trans-
duction upon interaction with OX40L on APCs in im-
mune responses (24). OX40L expression was previously
detected on activated B and dendritic cells (19, 20, 25).
Since the sensitivity in detection of OX40L expression
with soluble OX40 is at least 10 times lower than that with
MGP34 mAb (compare Fig. 2, A and C), MGP34 mAb is
useful as a sensitive assay in determining the expression ki-
netics of OX40L. Using MGP34 mAb, we found that CD40-
stimulated B and dendritic cells express OX40L within 2 d
of stimulation and are able to sustain this expression beyond
day 7. Since expression of CD40L, as a CD40 stimulant, is
immediately induced on T cells after antigen stimulation,
and since CD40 is constitutively expressed on APCs inde-
pendent of antigen stimulation (38, 39), our findings indi-
cate that OX40L expression is presumably induced by CD40
stimulation 2 d after antigen challenge. On the other hand,
OX40 expression on CD41 T cells has been reported to
peak 48 h after TCR stimulation (24), which coincides
with the onset of OX40L expression on CD40-stimulated
APCs. This sequential expression of CD40–CD40L and
OX40–OX40L suggests that the latter participates in the
later phase of in vivo T cell priming.
Furthermore, we monitored the expression of CD80,
CD86, and MHC class II molecules, known to be upregu-
lated on B and dendritic cells after CD40 stimulation (14,
25, 40). Normal upregulation of the molecules was ob-
served in OX40L-deficient APCs (data not shown), indi-
cating that the OX40L deficiency may be responsible for
the defective APC function in our study. As only partial
suppression of recall response was observed, an OX40–
OX40L-independent system may come into play. Indeed,
the synergistic potential of the CD28–CD80–CD86 and
OX40–OX40L systems in T cell activation has been sug-
gested by the findings that in vitro T cell activation was
markedly suppressed by a combination of both OX40L and
CD28 blockade, rather than either alone (14, 25). Other
costimulatory systems such as CD28–CD80–CD86 may
cooperatively work with the OX40–OX40L system in an-
tigen-specific T cell priming.
Since CD40 signaling is known to be upstream in the path-
way for nuclear factor kB activation (41), our findings depict-
ing the requirement of CD40 stimulation in the induction of
OX40L expression are consistent with our previous report
showing the downstream upregulation of the promoter activ-
ity of OX40L by nuclear factor kB activation (42).
Engagement of CD40 on APCs is well known to be an
essential event for the differentiation of APCs to become
functional in the priming of antigen-specific T cells (30, 43).
Impairment of in vivo T cell priming in response to protein
antigens in CD40L-deficient mice (30) appears to correlate
well with our data here with OX40L-deficient mice. In
addition, we demonstrated that CD40 signaling is a critical
trigger for inducing OX40L expression on APCs, and that
CD40 signaling, required for proliferation of B cells and
differentiation of APCs, is intact in OX40L-deficient mice
as demonstrated by normal expression of known CD40-
induced markers (data not shown). These results highlight
the close relationship between CD40 stimulation and OX40L
expression during the priming of T cells. We hypothesize
that the impairment of T cell priming in CD40- or CD40L-
deficient mice may be partially due to a failure of expres-
sion of OX40L on APCs. This plausible interplay of the two373 Murata et al.
systems in the subsequent development of an effective im-
mune response remains to be examined.
OX40 has been reported to be expressed on autoreactive
T cells in several autoimmune disorders, including in patients
with rheumatoid arthritis and graft-versus-host disease, and
in the mouse model of multiple sclerosis, EAE (7, 8, 11–14),
suggesting that the OX40–OX40L system may be involved
in autoimmune reactions. In vivo treatment with an sOX40
that blocks the interaction of OX40L with OX40 had a
therapeutic effect during EAE (14). Weinberg et al. (14) also
demonstrated that OX40L is expressed on a CD11b1 mac-
rophage/microglia cell population in the central nervous sys-
tem only during EAE onset, and that this population proba-
bly acts as APCs to activate the T cells causing EAE. In this
context, our findings using MGP34, antagonistic for OX40,
also encourage us to examine the clinical usefulness of the
blocking Ab in various autoimmune disorders.
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